21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
18:57 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Dermira discontinues development of acne candidate

Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor...
18:33 , Mar 5, 2018 |  BC Extra  |  Clinical News

Dermira plummets after Phase III acne failure

Dermira Inc. (NASDAQ:DERM) slid $16.57 (66%) to $8.59 on Monday after it said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two Phase III trials to treat moderate to severe acne vulgaris. The company...
14:46 , Aug 11, 2017 |  BC Week In Review  |  Company News

Dermira to develop Genentech's failed asthma candidate for atopic dermatitis

Dermira Inc. (NASDAQ:DERM) will revive development of lebrikizumab, this time for atopic dermatitis, after the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) discontinued its development following mixed results from two Phase III trials for severe...
00:10 , Aug 9, 2017 |  BC Extra  |  Company News

Dermira to develop Genentech's failed asthma candidate for atopic dermatitis

Dermira Inc. (NASDAQ:DERM) will revive development of lebrikizumab, this time for atopic dermatitis, after the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) discontinued its development following mixed results from two Phase III trials for severe...
21:21 , May 10, 2017 |  BC Extra  |  Clinical News

AZ's asthma candidate misses in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in the Phase III STRATOS 1 trial to treat severe uncontrolled asthma. Compared to placebo, the human IgG4 mAb against IL-13 did not significantly...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-13 (IL-13); IL-4 receptor (CD124; IL-4RA)

Hepatic disease INDICATION: Liver disease Mouse studies suggest inhibiting IL-13-CD124 signaling could help treat schistosomiasis-related liver disease. In a mouse model of Schistosoma mansoni infection, hepatoblast-specific knockout of IL-13 decreased recruitment of inflammatory cells to the liver...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Lebrikizumab: Phase III data

Top-line data from the identical, double-blind, international Phase III LAVOLTA I and LAVOLTA II trials in >2,100 patients total with severe uncontrolled asthma despite treatment with inhaled corticosteroids and a second controller medication showed that...
02:10 , Mar 1, 2016 |  BC Extra  |  Clinical News

Mixed results for Roche's lebrikizumab in asthma

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said lebrikizumab ( RG3637) met the primary endpoint of reducing the rate of asthma exacerbations over 52 weeks vs. placebo in the Phase III LAVOLTA I trial...
08:00 , Feb 8, 2016 |  BioCentury  |  Product Development

Asthma armament

Amgen Inc.'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline - or by any other targeted therapies in the clinic. The mAb has a...